메뉴 건너뛰기




Volumn 44, Issue 1, 2006, Pages 38-48

Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union

Author keywords

Bioavailability; Bioequivalence; Food interaction; Modified release products; Nifedipine

Indexed keywords

NIFEDIPINE; SANDOZ RETARD;

EID: 30644476227     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44038     Document Type: Article
Times cited : (43)

References (19)
  • 1
    • 0004069412 scopus 로고    scopus 로고
    • Draft guidance for industry: Food-effect bioavailability and bioequivalence studies
    • Anonymous US department of health and human services, Food and drug administration, CDER
    • Anonymous 1997 Draft guidance for industry: food-effect bioavailability and bioequivalence studies. US department of health and human services, Food and drug administration, CDER
    • (1997)
  • 2
    • 0242700681 scopus 로고    scopus 로고
    • Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation)
    • Anonymous The European Agency for the evaluation of medicinal products, CPMP/EWP/280/96
    • Anonymous 1999 Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation). The European Agency for the evaluation of medicinal products, CPMP/EWP/280/96
    • (1999)
  • 3
    • 0003484310 scopus 로고    scopus 로고
    • Draft guidance for industry: Bioanalytical method validation
    • Anonymous US department of health and human services, Food and drug administration, CDER, CVM
    • Anonymous 2001 Draft guidance for industry: bioanalytical method validation. US department of health and human services, Food and drug administration, CDER, CVM
    • (2001)
  • 4
    • 0032749958 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
    • Chung M, Vashi V, Puente J, Sweeney M, Meredith PA 1999 Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 48: 678-687
    • (1999) Br J Clin Pharmacol , vol.48 , pp. 678-687
    • Chung, M.1    Vashi, V.2    Puente, J.3    Sweeney, M.4    Meredith, P.A.5
  • 6
    • 0028235611 scopus 로고
    • Concentration-effect analysis of antihypertensive drug response - Focus on calcium antagonists
    • Donnelly R, Elliott HL, Meredith PA 1994 Concentration-effect analysis of antihypertensive drug response - focus on calcium antagonists. Clin Pharmacokinetic 26: 472-485
    • (1994) Clin Pharmacokinetic , vol.26 , pp. 472-485
    • Donnelly, R.1    Elliott, H.L.2    Meredith, P.A.3
  • 7
    • 0030045954 scopus 로고    scopus 로고
    • The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties
    • Grund JS, Foster RT 1996 The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet 30: 28-51
    • (1996) Clin Pharmacokinet , vol.30 , pp. 28-51
    • Grund, J.S.1    Foster, R.T.2
  • 8
    • 0028966473 scopus 로고
    • In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product
    • Hwang SS, Gorsline J, Louie J, Dye D, Guinta D, Hamel L 1995 In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product. J Clin Pharmacol 35: 259-267
    • (1995) J Clin Pharmacol , vol.35 , pp. 259-267
    • Hwang, S.S.1    Gorsline, J.2    Louie, J.3    Dye, D.4    Guinta, D.5    Hamel, L.6
  • 9
    • 0021931030 scopus 로고
    • Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle
    • Karim A, Burns T, Wearly L, Streicher J, Palmer M 1985a Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther 38: 77-83
    • (1985) Clin Pharmacol Ther , vol.38 , pp. 77-83
    • Karim, A.1    Burns, T.2    Wearly, L.3    Streicher, J.4    Palmer, M.5
  • 10
    • 0022392154 scopus 로고
    • Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption
    • Karim A, Burns T, Janky D, Hurwitz A 1985b Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther 38: 642-647
    • (1985) Clin Pharmacol Ther , vol.38 , pp. 642-647
    • Karim, A.1    Burns, T.2    Janky, D.3    Hurwitz, A.4
  • 12
    • 0023145387 scopus 로고
    • Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans
    • Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD 1987 Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 47: 26-30
    • (1987) Clin Pharmacol Ther , vol.47 , pp. 26-30
    • Kleinbloesem, C.H.1    van Brummelen, P.2    Danhof, M.3    Faber, H.4    Urquhart, J.5    Breimer, D.D.6
  • 13
    • 4344566603 scopus 로고    scopus 로고
    • Dihydropyridine calcium channel blockers: Basic pharmacological similarities but fundamental therapeutic differences
    • Meredith PA, Elliott HL 2004 Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 22: 1641-1648
    • (2004) J Hypertens , vol.22 , pp. 1641-1648
    • Meredith, P.A.1    Elliott, H.L.2
  • 14
    • 0035987168 scopus 로고    scopus 로고
    • The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: Pronounced lag-time after a high fat breakfast
    • Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH 2002a The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 53: 582-588
    • (2002) Br J Clin Pharmacol , vol.53 , pp. 582-588
    • Schug, B.S.1    Brendel, E.2    Chantraine, E.3    Wolf, D.4    Martin, W.5    Schall, R.6    Blume, H.H.7
  • 15
    • 0036118842 scopus 로고    scopus 로고
    • Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union
    • Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH 2002b Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 15: 279-285
    • (2002) Eur J Pharm Sci , vol.15 , pp. 279-285
    • Schug, B.S.1    Brendel, E.2    Wolf, D.3    Wonnemann, M.4    Wargenau, M.5    Blume, H.H.6
  • 16
    • 85019292399 scopus 로고    scopus 로고
    • Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast
    • Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH 2002c Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 58: 119-125
    • (2002) Eur J Clin Pharmacol , vol.58 , pp. 119-125
    • Schug, B.S.1    Brendel, E.2    Wonnemann, M.3    Wolf, D.4    Wargenau, M.5    Dingler, A.6    Blume, H.H.7
  • 18
    • 30644473558 scopus 로고    scopus 로고
    • Nifedipine extended release tablet/BAY a 1040/calcium antagonist Investigator's brochure/Bayer AG
    • Wagener G 2001 Nifedipine extended release tablet/BAY a 1040/calcium antagonist Investigator's brochure/Bayer AG: 8: 1-55
    • (2001) , vol.8 , pp. 1-55
    • Wagener, G.1
  • 19
    • 33646671392 scopus 로고    scopus 로고
    • Multisource (Generic) Pharmaceutical Products: Draft Guideline on Registration Requirements to establish interchangeability
    • World Health Organization QAS/04.093
    • World Health Organization 2004 Multisource (Generic) Pharmaceutical Products: Draft Guideline on Registration Requirements to establish interchangeability. QAS/04.093
    • (2004)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.